Evidence map›Paper›PMID 41303643›Full record

ArticleInternational journal of molecular sciences2025

Semaphorin3A Rewires CD4

Raeda Mubariki, Nasren Eiza, Adi D Sabag, Shiri Keret, Doron Rimar, Gleb Slobodin, Devy Zisman, Elias Toubi, Zahava Vadasz

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raeda MubarikiProteomic Unit, Bnai Zion Medical Center, Haifa 3478403, Israel.
Nasren EizaProteomic Unit, Bnai Zion Medical Center, Haifa 3478403, Israel.
Adi D SabagProteomic Unit, Bnai Zion Medical Center, Haifa 3478403, Israel.
Shiri KeretRheumatology Unit, Bnai Zion Medical Center, Haifa 3478403, Israel.
Doron RimarRheumatology Unit, Bnai Zion Medical Center, Haifa 3478403, Israel.
Gleb SlobodinRheumatology Unit, Bnai Zion Medical Center, Haifa 3478403, Israel.
Devy ZismanRheumatology Out-Patient Clinic, "Lin"-Clalit Health Services (OMG), Haifa 3478403, Israel.ORCID 0000-0003-0523-2292
Elias ToubiRappaport Faculty of Medicine, Technion, Haifa 3478403, Israel.
Zahava VadaszProteomic Unit, Bnai Zion Medical Center, Haifa 3478403, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Semaphorin3A (Sema3A) is a regulatory protein found to be expressed on regulatory T and B cells and also secreted into peripheral blood. It has been identified as a potent immune regulator; however, not all its regulatory mechanisms have been evaluated. In this respect, we aim to investigate how Sema3A affects key metabolic pathways in T cells during homeostasis and rheumatoid arthritis (RA), and on the AKT/mTORC1 signaling axis. In this study, peripheral blood samples were collected from 119 healthy donors and 32 rheumatoid arthritis patients. T cells were subjected to Seahorse analysis to evaluate OXPHOS and glycolysis, live cell TMRE staining to evaluate mitochondrial activity, mass spectrometry for metabolite profiling, ATP determination to study ATP production, and Western blot analysis to investigate the signaling pathway activity. This study presents evidence showing that Sema3A inhibits the AKT/mTORC1 pathway, leading to a decreased glucose uptake and glycolysis disruption. Furthermore, we show that Sema3A reduces mitochondrial capacity and OXPHOS in activated T cells of healthy and RA donors, leading to a decreased ATP production. In contrast, Sema3A upregulates fatty acid oxidation (FA), probably as a backup pathway to ensure cell survival. Results with

Indexed as

Arthritis, RheumatoidCD4-Positive T-LymphocytesMechanistic Target of Rapamycin Complex 1Proto-Oncogene Proteins c-aktSemaphorin-3AAdultAgedFemaleGlycolysisHumansMaleMiddle AgedMitochondriaOxidative PhosphorylationSignal TransductionMechanistic Target of Rapamycin Complex 1Proto-Oncogene Proteins c-aktSEMA3A protein, humanSemaphorin-3Aactivated T cellsfatty acid metabolismhomeostasisimmunometabolismoxidative phosphorylationrheumatoid arthritisSema3A

Identifiers

PMID41303643
PMCPMC12652675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.